BLPH — Bellerophon Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.23m
- -$4.15m
- 13
- 83
- 29
- 37
Annual income statement for Bellerophon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 27.9 | 17.5 | 26.3 | 20.2 | 22.4 |
| Operating Profit | -27.9 | -17.5 | -26.3 | -20.2 | -22.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.63 | -15.1 | -26.9 | -19.6 | -22.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.81 | -13.3 | -24.7 | -17.8 | -19.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.81 | -13.3 | -24.7 | -17.8 | -19.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.81 | -13.3 | -24.7 | -17.8 | -19.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.649 | -2.95 | -3.17 | -1.84 | -2.08 |